Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.

By J. Wright, G. Bakris, Tom Greene, L. Agodoa, L. Appel, J. Charleston, D. Cheek, Janice E G Douglas-Baltimore, J. Gassman, R. Glassock and 7 more. Journal of the American Medical Association (JAMA), 2002

2,073 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Nephrology, Nutrition and Dietetics

View Paper: https://www.semanticscholar.org/paper/558a4daf1f02054dc1670636dac483ed16e8c39a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

In Nephrology

Citations in the corpus

Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. (2004, result): “Metoprolol failed to decrease microalbuminuria, a finding also observed in the African-American Study of Kidney Disease trial with long-acting metoprolol.(36) This result may be related to an improvement in insulin resistance as noted by differences in the HOMA-IR index or an effect on oxidant stres”
Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality (2014, background): “4) Aichi 2002-06 14 1,791 2 (2-2) 0 28 8 (2) 11 1,489 3 (2-4) 0 17 6 (1) AKDN 2003-06 39,689 269,652 2 (2-3) 366 88 2 (1) 5,794 8,456 2 (1) 28,121 202,349 4 (3-6) 94 43 1 (0.”
Progression of Chronic Kidney Disease: The Role of Blood Pressure Control, Proteinuria, and Angiotensin-Converting Enzyme Inhibition: A Patient-Level Meta-Analysis (2003, methodology): “It is also consistent with the results of the MDRD Study (6, 7) and the AASK (11), which showed that lowering blood pressure in patients with higher but not lower levels of urine protein excretion had a greater beneficial effect on kidney disease progression.”
The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. (2013, background): “3), these observational data are not supported by the results of three trials in which CKD patients were randomized to a lower (<125– 130 mmHg) or higher (<140 mmHg) BP target [304–306]: no difference in renal failure or death was found between the two arms, except in the observational follow-up of ”
Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. (2016, background): “Results Search Results and Characteristics of Included Studies The literature search yielded 1,650 articles of which 67 were reviewed in full text and from which 15 randomized controlled trials reported in 17 publications were identified (Figure 1) [16– 18,22–35].”
Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. (2003, result): “Trials completed in the last decade were usually larger than the early trials, and some of them recruited special populations, including individuals with diabetes,(56,58,60,66,67) older adults,(41,42,45,53) those with a history of cerebrovascular disease,(25,50,65) and blacks with renal disease.(62,”
Predictors of new-onset kidney disease in a community-based population. (2004, background): “The African American Study of Kidney Disease and Hypertension trial showed no benefit of more rigorous blood pressure control (goal mean arterial pressure, 92 mm Hg; achieved blood pressure, 128/78 mm Hg) compared with usual blood pressure control (goal mean arterial pressure, 102-107 mm Hg; achieve”